Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
<b>Background</b>: Among rheumatologic diseases following therapy with immune checkpoint inhibitors (ICIs), the cases of cancer patients diagnosed as having polymyalgia rheumatica (PMR), particularly with nivolumab and pembrolizumab, has been steadily rising in published reports. <b&g...
Saved in:
Main Authors: | Ciro Manzo, Marco Isetta, Alberto Castagna, Melek Kechida |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-04-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3271/13/2/34 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01) -
REVIEW OF RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA (ACR/EULAR 2015)
by: M. T. Vatutin, et al.
Published: (2016-03-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01) -
A Case of PMR‐Like irAE Developing After Treatment With Ipilimumab and Nivolumab for Lung Cancer
by: Ryuichi Utsumi, et al.
Published: (2025-06-01) -
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)